15 June Price surfing the 10SMA and making lower highs There are two large momentum candles bringing price above the consolidation. It was also one of the rare stocks that was green while the broader market was red Risk I know the reason for the new pricing but I am unable to determine if it is so impactful that it justifies a 122% spike. But technicals seem to...
Insmed ( NASDAQ:INSM ), a biotech company, has successfully developed a lung disease drug, brensocatib, which has been shown to significantly reduce the frequency of respiratory symptoms such as chronic cough in a late-stage study. The drug, which is expected to be launched in mid-2025, is expected to be approved by the FDA in the fourth quarter of this year. The...
NASDAQ:INSM Possible Scenario: LONG Evidence: Price Action, Money Flow Period: Less than two months. TP1: 28.5$ TP2: 29.5$ TP3: 31$ *This is my idea and could be wrong 100%.
I see a repeating divergence in INSM for a decent short play after this market maker finishes with a target of 7.50
Today we entered positions with ROKU, BYND, and INSM. Started off the day with a loss, but cut my losses quick and looked for other opportunities.